Form 4: Vivani Medical Director Daniel Bradbury Reports New Stock Option Grant and Clerical Correction

Vivani Medical, Inc. Director and 10% Owner Daniel Bradbury reported the acquisition of 35,135 non-qualified stock options and a clerical correction to a previously reported option grant, as detailed in a recent SEC Form 4 filing.

Summary

• Daniel Bradbury, a Director and 10% Owner of Vivani Medical, Inc. (VANI), filed a Form 4 to report changes in his beneficial ownership of derivative securities.
• On June 24, 2025, Mr. Bradbury was granted 35,135 non-qualified stock options with an exercise price of $1.27 per share, as an annual grant pursuant to the Issuer's Non-Employee Director Compensation Policy.
• These newly granted options are set to vest in total on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to continued service.
• The filing also included an adjustment to a previously reported non-qualified stock option grant from January 1, 2025, correcting a clerical error that reduced the reported amount from 50,059 to 49,822 shares, a decrease of 237 options.
• Following these transactions, Daniel Bradbury beneficially owns a total of 84,957 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports routine insider transactions, including an expected annual option grant and a minor clerical correction. While not overwhelmingly positive, the grant of options aligns director interests with shareholders, and the correction of an error is a positive sign of transparency. No significant negative implications are present.

Positives

• The grant of 35,135 new non-qualified stock options to a director aligns his interests with shareholders, incentivizing long-term company performance.
• The vesting schedule for the new options, tied to continued service, indicates a commitment from the director to the company.
• The correction of a clerical error demonstrates transparency and accuracy in financial reporting.

Negatives

• A clerical error was identified in a previously reported option grant, which, while corrected, indicates a minor administrative oversight in prior reporting.

Risks

• The value of the stock options is contingent on Vivani Medical, Inc.'s stock price exceeding the exercise price of $1.27 and $1.16, respectively, at the time of exercise.
• The vesting of the options is subject to Daniel Bradbury's continued service to the company; if his service ceases before vesting, the unvested options could be forfeited.

Future Outlook

The document primarily reports past and current insider transactions and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction. However, the vesting schedules for the stock options imply a continued service commitment from the director.

Management Comments

• The filing includes a signature by Adam Mendelsohn, Attorney-in-fact, on behalf of Daniel Bradbury, indicating the use of a Power of Attorney for SEC filings.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions. It reflects standard compensation practices for non-employee directors, often involving stock options to align their interests with long-term shareholder value. Such filings are common across publicly traded companies and do not inherently indicate a shift in broader industry trends, but rather individual compensation and ownership changes.

Comparison to Industry Standards

• The grant of non-qualified stock options to a director is a common form of equity compensation in the biotechnology and medical device industries, similar to practices at companies like Amgen or Medtronic, which often use stock-based awards to incentivize long-term performance and retention.
• The vesting schedule (one year or next annual meeting for new options, quarterly for older options) is typical for director compensation, aiming to ensure continued engagement and alignment with company goals.
• The exercise prices of $1.27 and $1.16 are specific to Vivani Medical's stock valuation at the time of grant and are consistent with market-based pricing for such awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns his financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is indicated, though the compensation policy for directors might be part of a broader compensation philosophy.
• Management: The Power of Attorney streamlines compliance for the director and the company's legal/compliance team.

Next Steps

• Continued service by Daniel Bradbury to ensure vesting of stock options.
• Future SEC filings (Form 4 or 5) will report any further changes in Daniel Bradbury's beneficial ownership.
• The next annual meeting of stockholders will be a key date for the vesting of the newly granted options.

Key Dates

Recommendation

Keywords

Vivani Medical, VANI, SEC Form 4, Stock Options, Director Compensation, Insider Trading, Beneficial Ownership, Equity Compensation, Daniel Bradbury